Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2
Phase 4
- Conditions
- Chronic Kidney Disease Stage 1Chronic Kidney Disease Stage 2
- Interventions
- Drug: placebo
- Registration Number
- NCT01561222
- Lead Sponsor
- Taixing People's Hospital
- Brief Summary
Vitamin D Supplement in patients with CKD stage 1 and 2 may change osteoprotegin expression so as to produce beneficial effects of cardiovascular、bone metabolism and CKD progression.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Clinical diagnosis of CKD stage 1 and 2
- Age >18 years
- Ability to provide informed consent
Exclusion Criteria
- On vitamin D in past 4 weeks
- Plans to relocate out of Taixing City in the next one year
- Serum phosphate >5.5 mg/dl in past 3 months
- Serum calcium >10.0 mg/dl in past 3 months
- Cancer
- Transplanted organ
- Rapidly deteriorating kidney function with the expectation for initiation of dialysis in less than 6 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Calcitriol Calcitriol - placebo placebo -
- Primary Outcome Measures
Name Time Method Osteoprotegin level one year To assess the effect of vitamin D supplementation on osteoprotegin level in CKD patients
- Secondary Outcome Measures
Name Time Method Bone mineral density one year To assess the effect of vitamin D supplementation on bone mineral density in patients with CKD stage 1 and 2
vascular calcification score one year To assess the effect of vitamin D supplementation on vascular calcification score through performing lateral abdominal radiography or CT-based techniques in patients with CKD stage 1 and 2
Trial Locations
- Locations (1)
Taixing People's Hospital
🇨🇳Taixing, Jiangsu, China